Positron emission tomography in pediatric radiation oncology: Integration in the treatment-planning process

Pediatric Radiology

Volumn 34, Issue 3, 2004, Pages 214-221

  Krasin, Matthew J ^a   Hudson, Melissa M ^a,b   Kaste, Sue C ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Hodgkin's disease; Pediatric radiation oncology; Positron emission tomography; Treatment planning process

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CHILDHOOD CANCER; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER SIMULATION; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; OBSERVER VARIATION; OUTCOMES RESEARCH; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; TREATMENT PLANNING;

ADOLESCENT; CHILD; HODGKIN DISEASE; HUMANS; NEOPLASMS; PATIENT CARE MANAGEMENT; RADIATION ONCOLOGY; RADIOTHERAPY, ADJUVANT; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 1642335524     PISSN: 03010449     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00247-003-1113-4     Document Type: Article

References (33)

1. Pirotte B, Goldman S, Salzberg S, et al (2003) Combined positron emission tomography and magnetic resonance imaging for the planning of stereotactic brain biopsies in children: Experience in 9 cases. Pediatr Neurosurg 38:146-155
2. Bredella MA, Caputo GR, Steinbach LS (2002) Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. AJR Am J Roentgenol 179:1145-1150
3. Kushner BH, Yeung HW, Larson SM, et al (2001) Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 19:3397-3405
4. Mutic S, Malyapa RS, Grigsby PW, et al (2003) PET-guided IMRT for cervical carcinoma with positive para-aortic lymph nodes - a dose-escalation treatment planning study. Int J Radiat Oncol Biol Phys 55:28-35
5. Erdi YE, Rosenzweig K, Erdi AK, et al (2002) Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 62:51-60
6. Mah K, Caldwell CB, Ung YC, et al (2002) The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: A prospective study. Int J Radiat Oncol Biol Phys 52:339-350
7. Mutic S, Grigsby PW, Low DA, et al (2002) PET-guided three-dimensional treatment planning of intracavitary gynecologic implants. Int J Radiat Oncol Biol Phys 52:1104-1110
8. Caldwell CB, Mah K, Ung YC, et al (2001) Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: The impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys 51:923-931
9. Photon Treatment Planning Collaborative Working Group (1991) State-of-the-art of external photon beam radiation treatment planning. Int J Radiat Oncol Biol Phys 21:9-23
10. Intensity Modulated Radiation Therapy Collaborative Working Group (2001) Intensity-modulated radiotherapy: Current status and issues of interest. Int J Radiat Oncol Biol Phys 51:880-914
11. Kunkel M, Forster GJ, Reichert TE, et al (2003) Radiation response noninvasively imaged by [18F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma. Oral Oncol 39:170-177
12. Kato H, Kuwano H, Nakajima M, et al (2002) Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 184:279-283
13. Xia P, Pickett B, Vigneault E, et al (2001) Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys 51:244-254
14. Cohade C, Osman M, Pannu HK, et al (2003) Uptake in supraclavicular area fat ("USA-Fat"): description on 18F-FDG PET/CT. J Nucl Med 44:170-176
15. Vranjesevic D, Schiepers C, Silverman DH, et al (2003) Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. J Nucl Med 44:1238-1242
16. Beaulieu S, Kinahan P, Tseng J, et al (2003) SUV varies with time after injection in (18)F-FDG PET of breast cancer: Characterization and method to adjust for time differences. J Nucl Med 44:1044-1050
17. Vesselle HJ, Miraldi FD (1998) FDG PET of the retroperitoneum: Normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. Radiographics 18:805-823
18. Mutic S, Dempsey JF, Bosch WR, et al (2001) Multimodality image registration quality assurance for conformal three-dimensional treatment planning. Int J Radiat Oncol Biol Phys 51:255-260
19. Dizendorf E, Hany TF, Buck A, et al (2003) Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med 44:732-738
20. Demura Y, Tsuchida T, Ishizaki T, et al (2003) 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 44:540-548
21. Wong RJ, Lin DT, Schoder H, et al (2002) Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 20:4199-4208
22. Ioannidis JP, Lau J (2003) 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: A meta-analysis. J Nucl Med 44:717-724
23. Osman MM, Cohade C, Nakamoto Y, et al (2003) Clinically significant inaccurate localization of lesions with PET/CT: Frequency in 300 patients. J Nucl Med 44:240-243
24. Donaldson SS, Hudson MM, Lamborn KR, et al (2002) VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: Results of a prospective clinical trial. J Clin Oncol 20:3081-3087
25. Donaldson SS, Link MP (1987) Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J Clin Oncol 5:742-749
26. Hunger SP, Link MP, Donaldson SS (1994) ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: The Stanford experience. J Clin Oncol 12:2160-2166
27. Hudson MM, Greenwald C, Thompson E, et al (1993) Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol 11:100-108
28. Oberlin O, Leverger G, Pacquement H, et al (1992) Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: The experience of the French Society of Pediatric Oncology. J Clin Oncol 10:1602-1608
29. Weiner MA, Leventhal B, Brecher ML, et al (1997) Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol 15:2769-2779
30. Landman-Parker J, Pacquement H, Leblanc T, et al (2000) Localized childhood Hodgkin's disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy - results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 18:1500-1507
31. Ruhl U, Albrecht M, Dieckmann K, et al (2001) Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: An interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 51:1209-1218
32. Friedmann AM, Hudson MM, Weinstein HJ, et al (2002) Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. J Clin Oncol 20:3088-3094
33. Smith RS, Chen Q, Hudson MM, et al (2003) Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol 21:2026-2033